Management of peripheral T-cell non-Hodgkin's lymphoma

被引:25
作者
Horwitz, Steven M. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
关键词
high-dose therapy; non-Hodgkin's lymphoma; prognosis; T-cell lymphoma; therapy;
D O I
10.1097/CCO.0b013e3282ce6f8f
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of review Peripheral T-cell lymphomas are an uncommon and heterogeneous group of non-Hodgkin's lymphomas that are noted for their particularly poor prognosis. Their rarity has resulted in few data being available to allow formulation of optimal treatment approaches. There remains no widely accepted standard therapy. A new and increasing interest in studying these lymphomas is leading to advances in our understanding, which is widening options for management. Recent findings Historically, peripheral T-cell lymphomas were treated with strategies borrowed from management of aggressive B-cell lymphomas. Investigators have recognized the inadequacy of these approaches, and we are beginning to receive results, often preliminary, of studies specifically designed to evaluate T-cell lymphomas. These range from transplantation approaches, to better prognostic schemes and to attempts at molecular characterization, and new drugs are being developed specifically for their activity against T-cell lymphomas. Summary Research in T-cell lymphomas is still mainly preliminary and studies tend to be small. Nonetheless, our understanding of these disorders increasing, and data on new and hopefully better approaches are emerging.
引用
收藏
页码:438 / 443
页数:6
相关论文
共 34 条
[1]   New approach to classifying non-hodgkin's lymphomas: Clinical features of the major histologic subtypes [J].
Armitage, JO ;
Weisenburger, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2780-2795
[2]   Hepatosplenic γδ T-cell lymphoma is a rare clinicopathologic entity with poor outcome:: report on a series of 21 patients [J].
Belhadj, K ;
Reyes, F ;
Farcet, JP ;
Tilly, H ;
Bastard, C ;
Angonin, R ;
Deconinck, E ;
Charlotte, F ;
Leblond, V ;
Labouyrie, E ;
Lederlin, P ;
Emile, JF ;
Delmas-Marsalet, A ;
Arnulf, B ;
Zafrani, ES ;
Gaulard, P .
BLOOD, 2003, 102 (13) :4261-4269
[3]   High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas [J].
Blystad, AK ;
Enblad, G ;
Kvaloy, S ;
Berglund, Å ;
Delabie, J ;
Holte, H ;
Carlson, K ;
Kvalheim, G ;
Bengtsson, M ;
Hagberg, H .
BONE MARROW TRANSPLANTATION, 2001, 27 (07) :711-716
[4]   Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation [J].
Corradini, P. ;
Tarella, C. ;
Zallio, F. ;
Dodero, A. ;
Zanni, M. ;
Valagussa, P. ;
Gianni, A. M. ;
Rambaldi, A. ;
Barbui, T. ;
Cortelazzo, S. .
LEUKEMIA, 2006, 20 (09) :1533-1538
[5]   Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells [J].
Corradini, P ;
Dodero, A ;
Zallio, F ;
Caracciolo, D ;
Casini, M ;
Bregni, M ;
Narni, F ;
Patriarca, F ;
Boccadoro, M ;
Benedetti, F ;
Rambaldi, A ;
Gianni, AM ;
Tarella, C .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2172-2176
[6]  
DAMORE F, 2006, BLOOD, V108, pA401
[7]  
DANG N, 2006, BJH, V136, P439
[8]  
DELEVAL L, 2007, AM SOC HEMATOL, V109, P4952
[9]   Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma -: The MD Anderson Cancer Center experience [J].
Escalón, MP ;
Liu, NS ;
Yang, Y ;
Hess, M ;
Smith, TL ;
Dang, NH .
CANCER, 2005, 103 (10) :2091-2098
[10]   Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study [J].
Gallamini, A ;
Stelitano, C ;
Calvi, R ;
Bellei, M ;
Mattei, D ;
Vitolo, U ;
Morabito, F ;
Martelli, M ;
Brusamolino, E ;
Iannitto, E ;
Zaja, F ;
Cortelazzo, S ;
Rigacci, L ;
Devizzi, L ;
Todeschini, G ;
Santini, G ;
Brugiatelli, M ;
Federico, M .
BLOOD, 2004, 103 (07) :2474-2479